Journal ArticleOPEN ACCESS

Resistance to EGFR blockade in colorectal cancer: Liquid biopsies and latent subclones

Cell Research (2013) 23(1) 13-14
DOI: 10.1038/cr.2012.115
6Citations
Citations of this article
37Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Two recent papers identify KRAS activation as a mechanism of acquired resistance to EGFR blockade in colorectal cancer. In doing so, they suggest that resistance to single-agent EGFR blockade will be unavoidable because these alterations exist as latent subclones within the tumor even prior to the initiation of therapy. © 2013 IBCB, SIBS, CAS All rights reserved.

Cite

CITATION STYLE

APA

Konieczkowski, D. J., & Garraway, L. A. (2013). Resistance to EGFR blockade in colorectal cancer: Liquid biopsies and latent subclones. Cell Research, 23(1), 13–14. https://doi.org/10.1038/cr.2012.115

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free